Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina [Phase 2]

View source ↗

Summary

A Phase 2 study of IMB-1018972 for refractory angina was withdrawn; no results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina

Drugs mentioned

• IMB-1018972

Snippet

Sponsor: Imbria Pharmaceuticals, Inc. | Conditions: Refractory Angina | Phase 2 | Status: WITHDRAWN